A Dose Ranging Study Evaluating Efficacy and Safety of NI-03
Diseases of the Digestive System - Pancreas | Diseases of the Endocrine System
What is the purpose of this trial?
The purpose of this study is to determine the safety and efficacy of NI-03.
- Ages18 years - 85 years
- Trial withStason Pharmaceuticals, Inc.
- Start Date02/29/2020
- End Date07/30/2018
- Last Updated04/20/2020
- Study HIC#2000023420